Ipsogen Launches MapQuant Dx(TM) Genomic Grade Test To Identify Breast Cancer Patien
 

IPSOGEN SA (Marseilles, France and New Haven, CT, USA), a cancer profiler that markets molecular diagnostic assays for leukaemia announced that it is entering the breast cancer diagnostic market with the European launch of MapQuant Dx? Genomic Grade. MapQuant Dx? Genomic Grade is the very first molecular diagnostic test to accurately measure tumor grade, a consensus indicator of tumor proliferation, risk of metastasis and response to chemotherapy.

More...